ponsegromab

ESMO: Pfizer sees weight gain in cancer patients, aims to enter phase 3 in 2025
Fierce Biotech
Tue, 09/17/24 - 09:57 am
Pfizer
ESMO
cancer wasting
clinical trials
ponsegromab